A Randomized, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Using an Implanted Catheter and a SynchroMed II Pump.

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Using an Implanted Catheter and a SynchroMed II Pump.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs SNN 0031 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Newron Pharmaceuticals
  • Most Recent Events

    • 19 Jun 2013 Results were presented at the 17th International Congress of Parkinson's disease and Movement Disorders, according to a Newron Pharmaceuticals media release.
    • 14 Jun 2013 Results will be presented at the 17th International Congress of Parkinson's disease and Movement Disorders, according to a Newron Pharmaceuticals media release.
    • 24 Mar 2012 Last checked against European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top